Royal College of Nursing cuts ties with Israeli drug company
Summary
The Royal College of Nursing (RCN) in the UK ended its partnership with Teva UK, an Israeli drug company, due to concerns about the company’s military links and legal issues. The RCN made this decision after pressure from pro-Palestine groups and based on Teva’s history of legal sanctions and controversy.Key Facts
- The RCN represents over 500,000 nurses in the UK.
- Teva UK is part of Teva Pharmaceuticals, a major supplier of medicines to the NHS.
- The RCN stopped Teva UK from sponsoring a 2026 nursing event on migraine and headaches.
- The decision followed demands from groups Nurses for Palestine and UK Healthcare Petitions to Royal Colleges.
- Teva Pharmaceuticals has faced fines of about £1 billion for bribery, price-fixing, and blocking competition in various countries.
- In 2024, the EU fined Teva €462.6 million for anti-competitive actions related to a multiple sclerosis drug.
- In 2023, Teva agreed to pay $225 million in US fines for fixing drug prices, avoiding prosecution.
- Teva expressed disappointment and said it wants to continue discussions with the RCN, stating healthcare should stay focused on patients.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
